Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations (2013)

Meningiomas are the most common primary nervous system tumor. The tumor suppressor NF2 is disrupted in approximately half of meningiomas1 but the complete spectrum of genetic changes remains undefined. We performed whole-genome or whole-exome sequencing on 17 meningiomas and focused sequencing on an additional 48 tumors to identify and validate somatic genetic alterations. Most meningiomas Read more about Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations (2013)[…]

Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas (2016)

Meningiomas located in the skull base are surgically challenging. Recent genomic research has identified oncogenic SMOand AKT1 mutations in a small subset of meningiomas. METHODS The authors performed targeted sequencing in a large cohort of patients with anterior skull base meningiomas (n = 62) to better define the frequency of SMO and AKT1 mutations in Read more about Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas (2016)[…]

Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma (2016)

Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients. The frequency of such mutations in clinical cohorts and the presence of other actionable mutations in meningiomas are important to define.

A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus (2016)

Higher-grade meningiomas (HGMs; World Health Organization grades II and III) pose a clinical problem due to high recurrence rates and the absence of effective therapy. Preclinical development of novel therapeutics requires a disease model that recapitulates the genotype and phenotype of patient HGM. Oncolytic herpes simplex virus (oHSV) has shown efficacy and safety in cancers Read more about A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus (2016)[…]

Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5 (2014)

Meningiomas are a diverse group of tumors with a broad spectrum of histologic features. There are over 12 variants of meningioma, whose genetic features are just beginning to be described. Angiomatous meningioma is a World Health Organization (WHO) meningioma variant with a predominance of blood vessels. They are uncommon and confirming the histopathologic classification can Read more about Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5 (2014)[…]

Increased expression of the immune modulatory molecule PDL1 (CD274) in anaplastic meningioma (2014)

There are no effective medical treatments for WHO grade III (anaplastic) meningioma. Patients with this high-grade malignancy have a median survival of less than two years. Therapeutics that modulate the mechanisms that inhibit local immune responses in the tumor microenvironment are showing significant and durable clinical responses in patients with treatment refractory high-grade tumors. We Read more about Increased expression of the immune modulatory molecule PDL1 (CD274) in anaplastic meningioma (2014)[…]

Radiation treatment for WHO grade II and III meningiomas (2013)

The treatment of meningiomas is tailored to their histological grade. While World Health Organization (WHO) grade I lesions can be treated with either surgery or external beam radiation, WHO Grade II and III lesions often require a combination of the two modalities. For these high-grade lesions, conventional external beam radiation is delivered to either the Read more about Radiation treatment for WHO grade II and III meningiomas (2013)[…]